Home > Gastroenterology > Revised immunogenomic classification of liver cancer may help predict immunotherapy response

Revised immunogenomic classification of liver cancer may help predict immunotherapy response


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
Gut
Reuters Health - 11/03/2022 - A revised immunogenomic classification for hepatocellular carcinoma (HCC) includes several novel mechanisms of immune response and evasion and may help to better gauge outcome associated with immunotherapy in HCC, the developers say.  The advent of immune-checkpoint inhibitors (ICIs) has transformed the field of immune-oncology and revolutionized the management of cancer. In HCC, however, only about one in five patients mount a durable response.  A recent study found significant differences in clinical outcomes following ICI therapy based on underlying liver-disease etiology, with a much greater benefit in viral-related than in non...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on